You might say the recent launch of Interline Therapeutics comes down to community. There is the community of veteran biopharma executives and researchers who recently completed a $92 million in Series A financing that brought the nearly year-old startup out of stealth mode. Interline aims to elucidate the interactive networks of dynamic protein-protein interactions (PPIs), or “communities,” through which proteins function, but whose workings still remain largely unknown to researchers . . .